Trials / Recruiting
RecruitingNCT06745297
A Study in Healthy Men to Test How Well Different Doses of BI 3776528 Are Tolerated
A Two-part, Randomised, Single-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BI 3776528, Administered to Healthy Male Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The trial aims to study the safety, tolerability, and pharmacokinetics of single and multiple rising doses of BI 3776528.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3776528 | BI 3776528 |
| DRUG | Placebo matching BI 3776528 | Placebo matching BI 3776528 |
| DRUG | short-acting benzodiazepine | short-acting benzodiazepine |
Timeline
- Start date
- 2025-01-23
- Primary completion
- 2026-08-25
- Completion
- 2026-08-25
- First posted
- 2024-12-20
- Last updated
- 2025-11-21
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT06745297. Inclusion in this directory is not an endorsement.